-
公开(公告)号：EP3150699B2
公开(公告)日：2024-08-21
申请号：EP15800498.6
申请日：2015-05-27
CPC分类号： C07K14/505 , C12P21/005 , C07K14/59 , C07K2319/0920130101 , C07K2319/4120130101
-
-
公开(公告)号：EP3348635A1
公开(公告)日：2018-07-18
申请号：EP16844430.5
申请日：2016-09-08
IPC分类号： C12N15/09 , A61K38/00 , A61P5/10 , A61P19/00 , A61P43/00 , C07K14/765 , C07K19/00 , C12N5/16
CPC分类号： C07K14/765 , A61K38/00 , A61P3/00 , A61P5/06 , A61P43/00 , C07K14/61 , C07K19/00 , C07K2319/00 , C12N5/16 , C12N15/09
摘要： Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
-
公开(公告)号：EP2877575B1
公开(公告)日：2018-06-27
申请号：EP13822148.6
申请日：2013-07-24
发明人： ASANO, Masahiro , YAGI, Toshihiro , FUKUI, Tsuyoshi , KAWASAKI, Atsuko , HATANO, Yukichi , MIHARA, Kazutoshi , SUGIMURA, Atsushi
IPC分类号： C12N9/40
CPC分类号： C12N9/2465
摘要： Disclosed is a method for production of recombinant human alpha-galactosidase A (rh alpha-Gal A) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-Gal A-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, and (g) to gel filtration column chromatography, in the order.
-
5.发明公开
公开(公告)号：EP3315606A1
公开(公告)日：2018-05-02
申请号：EP16814464.0
申请日：2016-06-24
IPC分类号： C12N15/09 , A61K39/395 , A61K45/00 , A61P9/10 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/24 , A61P25/28 , A61P31/04 , A61P31/12 , A61P35/00 , C07K14/475 , C07K16/18 , C07K16/28 , C07K16/46 , C07K19/00
CPC分类号： C07K16/28 , A61K39/395 , A61K45/00 , A61K2039/505 , A61P25/00 , C07K14/475 , C07K14/505 , C07K14/7151 , C07K16/18 , C07K16/46 , C07K19/00 , C07K2317/24 , C07K2317/92 , C07K2319/30 , C12N5/10 , C12N9/10 , C12N9/14 , C12N9/16 , C12N9/24 , C12N9/2402 , C12N9/48 , C12N9/64 , C12N15/09 , C12N15/113 , C12Y301/02 , C12Y302/01076 , C12Y304/14009 , C12Y310/01001
摘要： Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.
摘要翻译： 公开了一种将具有生理或药理活性并且不能通过血脑屏障的化合物转化为允许它们穿过血脑屏障的形式以及由此转化的化合物的手段。 该手段是抗人转铁蛋白受体抗体，并且转化的化合物是生理活性蛋白质或药理活性低分子量化合物与抗人转铁蛋白受体抗体之间的分子缀合物。
-
公开(公告)号：EP2668272B1
公开(公告)日：2017-10-25
申请号：EP12739815.4
申请日：2012-01-23
发明人： MIHARA, Kazutoshi , KAWASAKI, Atsuko , OOTSUKI, Kouta , HATANO, Yuukichi , KAMEI, Shoichiro , SUGIMURA, Atsushi
CPC分类号： C12N9/16 , C12Y301/06013
-
公开(公告)号：EP2832850B1
公开(公告)日：2017-09-06
申请号：EP13768121.9
申请日：2013-03-28
发明人： IMAGAWA, Kiwamu
IPC分类号： C12N5/0775 , A61K35/32 , A61P19/08 , A61P37/06 , A61P43/00
CPC分类号： C12N5/0607 , A61K35/12 , A61K35/32 , C12N5/0664 , C12N2533/52 , C12N2533/54 , C12N2535/00 , C12N2535/10
摘要： Disclosed is a method for producing pluripotent stem cell-enriched human dental pulp-derived cells. The method is characterized in that it includes (a) culturing a dental pulp suspension in a feeder cells-culture vessel containing feeder cells whose proliferative ability is suppressed, on a membrane having micropores that can block passage of the feeder cells and supported in the feeder cells-culture vessel in a manner to prevent the lower side face thereof from contacting with the feeder cells, thereby preventing direct contact with the feeder cells, and, (b) a step for recovering the cells proliferating on the membrane.
-
公开(公告)号：EP2756855B1
公开(公告)日：2017-08-30
申请号：EP12831697.3
申请日：2012-09-10
CPC分类号： A61M5/31568 , A61M5/14566 , A61M5/1684 , A61M5/20 , A61M5/2066 , A61M5/31546 , A61M5/31576 , A61M5/31593 , A61M5/326 , A61M2005/14573 , A61M2005/206 , A61M2005/3125 , A61M2005/31588 , A61M2205/14 , A61M2205/215 , A61M2205/3606 , A61M2205/50
摘要： The pharmaceutical injection device includes a pharmaceutical syringe mounting portion (3) provided within a main body case (2) and to which a pharmaceutical syringe (4) is removably mounted, a piston (5) provided movably with respect to the pharmaceutical syringe (4) mounted to the pharmaceutical syringe mounting portion (3), a drive mechanism (6) for driving the piston (5), a controller (7) that is electrically connected to the drive mechanism (6), a display section (35) that is connected to the controller (7), and an encoder (26) that is connected to the controller (7) and detects the amount of the pharmaceutical remaining inside the pharmaceutical syringe (4). The controller (7) displays a warning on the display section (35) recommending removal of the pharmaceutical syringe (4) from the pharmaceutical syringe mounting portion (3) when the presence of a pharmaceutical is detected by the encoder (26).
摘要翻译： 该药剂注射装置具备：药剂注射器安装部（3），其设置在主体壳体（2）内，能够装卸地安装有药剂注射器（4）;活塞（5），其相对于药剂注射器（4）移动自如 ），其安装于药剂注射器安装部（3）;驱动机构（6），其用于驱动活塞（5）;控制器（7），其与驱动机构（6）电连接;显示部（35） 与控制器（7）连接，编码器（26）与控制器（7）连接，检测药剂注射器（4）内残留的药剂量。 当编码器（26）检测到药物的存在时，控制器（7）在显示部分（35）上显示警告，建议从药物注射器安装部分（3）移除药物注射器（4）。
-
公开(公告)号：EP2832850A1
公开(公告)日：2015-02-04
申请号：EP13768121.9
申请日：2013-03-28
发明人： IMAGAWA, Kiwamu
IPC分类号： C12N5/0775 , A61K35/32 , A61P19/08 , A61P37/06 , A61P43/00
CPC分类号： C12N5/0607 , A61K35/12 , A61K35/32 , C12N5/0664 , C12N2533/52 , C12N2533/54 , C12N2535/00 , C12N2535/10
摘要： Disclosed is a method for producing pluripotent stem cell-enriched human dental pulp-derived cells. The method is characterized in that it includes (a) culturing a dental pulp suspension in a feeder cells-culture vessel containing feeder cells whose proliferative ability is suppressed, on a membrane having micropores that can block passage of the feeder cells and supported in the feeder cells-culture vessel in a manner to prevent the lower side face thereof from contacting with the feeder cells, thereby preventing direct contact with the feeder cells, and, (b) a step for recovering the cells proliferating on the membrane.
摘要翻译： 公开了一种用于生产富含多能干细胞的人类牙髓来源的细胞的方法。 该方法的特征在于，包括：（a）将牙髓悬浮液在含有抑制增殖能力的饲养细胞的饲养细胞培养容器中培养在具有可阻塞饲养细胞通过并支持在饲养细胞中的微孔的膜上 以防止其下侧面与饲养细胞接触，从而防止与饲养细胞直接接触，和（b）回收在细胞膜上增殖的细胞的步骤。
-
公开(公告)号：EP2693212A1
公开(公告)日：2014-02-05
申请号：EP12762782.6
申请日：2012-03-26
发明人： YOKOYAMA, Tetsuo
CPC分类号： G01N21/6486 , G01N30/30 , G01N30/74 , G01N30/84 , G01N30/88 , G01N2030/3007 , G01N2030/8435 , G01N2030/8836 , Y10T436/143333
摘要： Disclosed are an apparatus and a method for separation analysis of mannose-6-phosphate (M6P) in reducing sugars without using boric acid in a post-column fluorescence detection method. The apparatus is an apparatus for separation analysis based on chromatography, which includes a column with a solid phase having affinity for phosphate, a flow path for the eluate, a heater installed on the flow path for causing M6P and a basic amino acid to react by heating the eluate in the flow path, and a fluorescence detector installed downstream of the heater for continuously irradiating the eluate with excitation light and measuring the intensity of the fluorescence emitted, and which may further include in the flow path a supply channel for addition of a basic amino acid between the column and the heater. The method is characterized in that it uses the apparatus and a second mobile phase consisting of a second buffer containing phosphate at a predetermined concentration and adjusted to a predetermined pH.
摘要翻译： 公开了一种用于在柱后荧光检测方法中不使用硼酸来分离还原糖中的甘露糖-6-磷酸（M6P）的设备和方法。 该装置是基于色谱的分离分析装置，其包括具有对磷酸有亲和力的固相的柱，洗脱液的流路，安装在流路上的用于使M6P与碱性氨基酸反应的加热器 加热流路中的洗脱液，以及安装在加热器下游的荧光检测器，用于连续地用激发光照射洗脱液并测量所发出的荧光的强度，并且还可以在流路中包括添加 色谱柱和加热器之间的碱性氨基酸。 该方法的特征在于它使用该设备和第二流动相，该第二流动相由含有预定浓度的磷酸盐并调节至预定pH的第二缓冲液组成。
-
-
-
-
-
-
-
-
-
搜索结果
199 条记录 (耗时 0.035 秒)
